Physician profile
Suzanne D Ford
NPI 1023066032
$18,706.43
in general payments reported to CMS, 2019-2025
44 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,906 · 2020: $2,346 · 2021: $2,664 · 2022: $2,382 · 2023: $2,914 · 2024: $3,289 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,348 · Education: $60.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,347.79 |
| Education | $60.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,424.57 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,971.64 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,448.04 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,121.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,091.79 | 2019-2025 | |
| Novo Nordisk INC | $976.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $954.06 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $953.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $906.44 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $726.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $673.21 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.00 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $533.42 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $496.81 | 2019-2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $439.77 | 2020-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $375.85 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $358.92 | 2019-2024 | Livalo, Seglentis |
| Grifols USA, LLC | $302.00 | 2021-2025 | Prolastin-C Liquid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $278.97 | 2024-2025 | Caplyta |
| Daiichi Sankyo INC. | $213.88 | 2019-2022 | |
| Amarin Pharma, INC. | $185.15 | 2019-2022 | |
| Astellas Pharma US INC | $180.74 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $152.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $142.20 | 2021 | |
| Verona Pharma, INC. | $120.17 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $118.70 | 2019-2022 | |
| Redhill Biopharma INC. | $114.26 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $105.27 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $102.26 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $83.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $75.39 | 2019-2024 | Eliquis |
| Axsome Therapeutics, INC. | $70.36 | 2024-2025 | Auvelity |
| Optinose US, INC. | $69.78 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $57.71 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $54.20 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $49.58 | 2023-2025 | Gvoke Hypopen |
| Ardelyx, INC. | $41.98 | 2025 | Ibsrela |
| Tris Pharma INC | $38.66 | 2023-2024 | Dyanavel Xr |
| Impel Pharmaceuticals INC. | $31.26 | 2023 | Trudhesa |
| Tonix Medicines, INC. | $25.08 | 2025 | Tonmya |
| Vanda Pharmaceuticals INC. | $24.63 | 2025 | Hetlioz, Fanapt |
| Indivior INC. | $18.07 | 2020 | |
| Antares Pharma, INC. | $16.91 | 2025 | Xyosted |
| Kerecis Limited | $7.60 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.